Herpes Simplex Virus (HSV) Vector Platform for CAR Engineering

Online Inquiry

Background Platforms What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a Herpes Simplex Virus (HSV) Vector Platform for CAR Engineering to accelerate the development of next-generation engineered immune therapies. This platform addresses challenges including limited cargo capacity of traditional viral vectors, integration-related safety concerns, and insufficient engineering flexibility for complex CAR designs. Leveraging the ultra-large cargo capacity, non-integrating episomal delivery characteristics, and advanced viral engineering capabilities of HSV vectors, Creative Biolabs supports the development of multi-antigen, armored, and functionally enhanced CAR systems.

Introduction

Solid tumor immunotherapy faces major hurdles, including heterogeneous antigen expression, poor T-cell trafficking, and strict vector cargo limits. Recent literature confirms that HSV-1 vectors overcome these barriers. The oncolytic HSV can deliver dual-target CAR modules and immunomodulators to turn "cold" solid tumors "hot". Furthermore, CAR-T cells loaded with oncolytic HSV act as effective transport vehicles, enabling systemic delivery to deep-seated tumors. Advances in non-replicative HSV genomic and amplicon design solidify HSV as a versatile, non-integrating platform for complex gene delivery.

Our Platforms

Creative Biolabs offers end-to-end vector design, generation, and testing services that overcome the physical and functional bottlenecks of traditional viral delivery systems. By leveraging the large double-stranded DNA genome (~152 kb) of HSV-1, our platform enables developers to package ultra-large and complex genetic cassettes that are impossible to fit into AAV (~4.7 kb) or Lentivirus (~8–10 kb) vectors.

Ultra-Large Cargo Accommodation: Package multi-cistronic cassettes, including dual or tri-target CARs, safety switches, co-stimulatory receptors, and local immunomodulatory cytokines into a single construct.
De-Risked Mutagenesis Profile: Utilize non-replicative HSV vectors or HSV amplicons that maintain expression as stable episomal DNA, eliminating random genomic insertion risks.
Tumor Microenvironment (TME) Remodeling: We engineer dual-functional oncolytic HSV constructs capable of eliminating tumor cells through lysis while inducing the expression of specific target antigens on the surface of solid tumor cells.
High-Titer and High-Purity Production: Our technical solutions incorporate optimized packaging systems, bacterial artificial chromosome (BAC)-mediated HSV genetic engineering, and scalable purification processes.

Discover How We Can Help - Request a Consultation.

What We Can Offer

We offer diverse HSV vector engineering solutions, including BAC-based high-precision HSV-1 genome modification, safe, non-replicative nrHSV-1 vectors with large transgene capacity, helper-free HSV amplicon vectors with ultra-large payload capability, and tumor-selective oncolytic oHSV vectors, alongside comprehensive in vitro and in vivo analytics for vector potency, CAR expression, and functional validation.

Platform of Herpes Simplex Virus (HSV) Vector Platform for CAR Engineering. (Creative Biolabs Original)

Our Workflow

To launch the HSV CAR engineering project, clients need to provide antigen and CAR sequence parameters, target host cell information, and customized requirements for vector type, titer, and purification standards.

Workflow of Herpes Simplex Virus (HSV) Vector Platform for CAR Engineering. (Creative Biolabs Original)

Clients receive aliquoted high-titer purified research-grade HSV vectors with storage instructions, a complete CoA including titer, purity, residuals and sequence confirmation, plus a functional potency report verifying transduction, CAR/payload expression and cell killing activity.

Benefits

Fully Customized Vector Engineering: End-to-end tailored services from bespoke vector backbone modification to custom promoter design and multi-cistronic 2A/IRES element assembly.
Rigorous Quality Control & Safety Testing: Comprehensive batch verification including physical/infectious titering, host nucleic acid and protein residual assays, replication-competency testing, and genomic integrity checks.
Integrated Downstream Potency Validation: One-stop functional evaluation covering in vitro cell line transduction, flow cytometric CAR surface density profiling, payload secretion quantification, and target-cell cytotoxicity kinetics.

FAQs

Q: Why choose HSV over Lentivirus/AAV for CAR engineering?

A: HSV features far larger cargo capacity (30–40 kb for non-replicative vectors, up to 150 kb for amplicons) versus 8–10 kb for lentivirus and 4.7 kb for AAV, enabling single-vector delivery of complex CAR circuits, armoring modules and safety elements. As non-integrating episomes, HSV vectors also eliminate insertional mutagenesis risks.

Q: Are HSV vectors safe for cell and gene therapy?

A: Yes. Non-replicative HSV vectors delete key immediate-early genes to block viral replication and cytotoxicity. Helper-free amplicons carry no viral coding sequences, ensuring high safety for ex vivo cell engineering and in vivo delivery.

Q: Can HSV support in vivo CAR delivery and combination therapy?

A: Yes. Oncolytic HSV (oHSV) selectively replicates in and lyses tumor cells, and can express CAR targets on tumor surfaces. This antigen-painting strategy empowers universal CAR-T cells to recognize and eliminate hard-to-target solid tumors.

Partner with Us

Creative Biolabs is a global partner in viral vector engineering, providing advanced solutions for complex cell and gene therapy applications. Our Herpes Simplex Virus (HSV) Vector Platform for CAR Engineering enables biopharmaceutical researchers to bypass traditional cargo constraints, engineer sophisticated multi-antigen immune circuits, and develop high-potency immuno-oncology therapies for hard-to-treat solid tumors. From BAC-based construct engineering and high-titer virus packaging to rigorous analytical potency testing, Creative Biolabs delivers reliable solutions tailored to your R&D objectives. You can get in touch with us if you aim to accelerate your cell therapy pipeline by adopting cutting-edge HSV vector technology, and our professional team consisting of biologists and viral engineers will provide full support for you.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.